20180315 PR AACR LB poster accepted
Author: alcyon
First Chronic Hepatitis B Patient Dosed in China in a Phase 1 Trial of T101 (Transgene’s TG1050 Technology)
20180117 PR FPI T101
First Patient Dosed in a Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC)
20180116 PR FPI TG4010 1L EN
Transgene Announces Financial Calendar for 2018
20171221 Financial calendar 2018 EN
Transgene Announces Upcoming Investor Meetings
20171218 PR financial agenda T1 18
BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors
BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors
Transgene to Present Additional Immunology Data from the TIME trial with TG4010 in patients with advanced lung cancer at SITC 2017
20171030 PR SITC TG4010
TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B
Martin F. Sprinzl, et al. AASLD & Hepatology, October 2017 Download the poster here Poster Presentation
First half-year 2017 in line with our objectives: All clinical programs progressing and new collaboration agreements signed
20170913 EN – CP Resultats financiers final
Transgene and Institut Bergonié Present a Poster on the METROmaJX Trial (Oncolytic Virus Pexa-Vec + Metronomic Cyclophosphamide) at ESMO 2017 Congress
20170907-ESMO-Metromajx-poster-EN